Fintech

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Globenewswire·March 30, 2026 at 11:30 AM

Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

NY Fed: Mobile Sports Betting Increases Credit Delinquency
PYMNTS
Labor Department Eases 401(k) Alternative Investment Access
PYMNTS
US rule may open trillions in 401(k) to crypto
CoinDesk
Businesses Adapt AI Budgeting to Usage-Based Pricing
PYMNTS

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing